ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Opinion|Videos|January 29, 2025
Suppression Therapy for Hypothyroidism and Risk Stratification
Author(s)Todd W. Frieze, MD
Todd W. Frieze, MD, discusses various suppression therapy approaches for patients with hypothyroidism and thyroid cancer.
Advertisement
Advertisement
Related to this article
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC and Crohn disease at 1 year.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Advertisement
Advertisement
Trending on Patient Care Online
1
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
2
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
3
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
4
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
5